Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs. Submitted IND application to FDA for our Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 in R/R NHL. Submitted CTA to EMA for our Phase 2 study of GLPG5201 in R/R CLL with or without RT. IND filing for our Phase 1/2 EUPLAGIA-1 study of CD19 CAR-T candidate GLPG520 ...